Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariaelena Pierobon

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Molecular Cancer Research : MCR|June 6, 2019
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma CellsErika Parasido, George S Avetian, Aisha Naeem, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Cell Reports|December 1, 2021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatmentJennifer E Klomp, Ye S Lee, Craig M Goodwin, et al.
Clinical Proteomics|January 23, 2024
Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsamplingAllison L Hunt, Nicholas W Bateman, Waleed Barakat, et al.
Cancer Discovery|October 26, 2019
Atypical KRAS<sup>G12R</sup> Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic CancerG Aaron Hobbs, Nicole M Baker, Anne M Miermont, et al.
Nature Cancer|June 6, 2022
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin H Lin, Justine C Rutter, Abigail Xie, et al.
Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
NPJ Precision Oncology|March 14, 2024
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilitiesNicholas W Bateman, Tamara Abulez, Anthony R Soltis, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Molecular Cancer Research : MCR|June 6, 2019
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma CellsErika Parasido, George S Avetian, Aisha Naeem, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Cell Reports|December 1, 2021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatmentJennifer E Klomp, Ye S Lee, Craig M Goodwin, et al.
Clinical Proteomics|January 23, 2024
Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsamplingAllison L Hunt, Nicholas W Bateman, Waleed Barakat, et al.
Cancer Discovery|October 26, 2019
Atypical KRAS<sup>G12R</sup> Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic CancerG Aaron Hobbs, Nicole M Baker, Anne M Miermont, et al.
Nature Cancer|June 6, 2022
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin H Lin, Justine C Rutter, Abigail Xie, et al.
Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
NPJ Precision Oncology|March 14, 2024
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilitiesNicholas W Bateman, Tamara Abulez, Anthony R Soltis, et al.
Pageof 10